Table 2.
Rank correlations and increased (+) or decreased (−) protein levels in given BC subsets. B, B cells; DA, dendritic cells activated; DR, dendritic cells resting; MA, Mast cell activated; MØ, Macrophages; NKA, NK cells activated; NKR, NK cells resting; T4, CD4 naive; T4A, CD4 memory activated; T4R, CD4 memory resting; T8, T cells CD8; Tfh, follicular helper; Tgd, gamma delta; Th, T helper; Treg, regulatory
| Chemokines | Cancer vs benign (1‐way ANOVA) | Grade (Kendall tau) | Ki67 (Spearman rank) | HER2 (Kendall tau) | ER (Spearman rank) | Comments and leukocyte subsetsa |
|---|---|---|---|---|---|---|
| CCL2b | + (P = 0.031) | + (P = 0.017) | + (P = 0.006) | − (P = 0.048) | Cluster. Th2/17/22c | |
| CCL3b | + (P = 0.0082) | + (P = 0.013) | + (P = 0.0099) | − (P = 0.025) | Cluster. Th1c | |
| CCL4b | + (P = 0.018) | + (P = 0.016) | + ( P = 4.0e‐4) * | − (P = 0.0048) | Cluster. NKA, MA, Th1/2/17/22c | |
| CCL7 | + ( P = 0.037) * | + (P = 0.0049) | + (P = 0.037) | M0, Th1, Th2 | ||
| CCL8b | + ( P = 0.037) * | + (P = 0.015) | + ( P = 5.7e‐4) * | − (P = 0.021) | Cluster. M1, M2, DA, Th2 | |
| CCL13 | + (P = 0.039) | + ( P = 9.5e‐4) * | + (P = 0.016) | In model. M2, DR, DA, Th2 | ||
| CCL17 | + (P = 0.036) | DR, DA, Th2/17/22 | ||||
| CCL19b | + (P = 0.0011) | M1, DA | ||||
| CCL20 | + (P = 0.0069) | + ( P = 7.4e‐5) * | − (P = 0.0023) | Cluster. T4A, DA, MA, Th17/22 | ||
| CCL23 | + (P = 0.0048) | In model. M2, Th1 | ||||
| CXCL1 | + (P = 0.021) | + (P = 0.0086) | − (P = 0.042) | Cluster | ||
| CXCL5 | − (P = 0.002)† | In model. M0 | ||||
| CXCL8 (IL‐8) | + (P = 0.0077) | + (P = 0.0063) | − (P = 0.017) | Cluster. Model. Inflammatory cytokine | ||
| CXCL9b | + ( P = 0.015) * | + (P = 0.018) | + ( P = 5.7e‐6) * | + (P = 0.010) | − (P = 0.0014) | Cluster. In model, M1 |
| CXCL10b | + ( P = 0.0068) * | + (P = 0.039) | + ( P = 1.4e‐4) * | + (P = 0.018) | − (P = 0.013) | Cluster. M1, DA, |
| CXCL11b | + ( P = 0.0016) * | + (P = 0.033) | + ( P = 1.3e‐4) * | + (P = 0.029) | − (P = 0.012) | Cluster. M1, DA, |
| CXCL13b | − (P = 0.0018) | + (P = 0.028) | − (P = 0.026) | Cluster. T4A, Tfh, M1c | ||
| CXCL17 | + ( P = 2.2e‐5) * | − ( P = 2.8e‐4) * | In model. | |||
| CX3CL1 | − (P = 0.064) | + (P = 0.020) | + (P = 0.031) | Cluster | ||
| CD markers | ||||||
| CD4 | + (P = 0.033) | + (P = 0.027) | T4R, Treg, M2 | |||
| CD5 | + (P = 0.017) | + ( P = 4.6e‐5) * | + (P = 0.0062) | − (P = 0.006) | Cluster. Treg | |
| CD8A | + (P = 0.016) | + ( P = 1.9e‐4) * | − (P = 0.0022) | Cluster. T8, Tfh | ||
| CD27 | + (P = 0.017) | + (P = 0.0033) | BC, T8, T4, T4R, Tfh, Treg | |||
| CD40 | + (P = 0.0033) | + (P = 0.002) | − (P = 0.013) | M1 | ||
| CD40L | + (P = 0.016) | + (P = 0.020) | − (P = 0.049) | T4, T4R, T4A, Tfh | ||
| CD48 | + (P = 0.0039) | + ( P = 3.1e‐4) * | + (P = 0.015) | − (P = 0.028) | ||
| CD137 (TNFRSF9) | + (P = 0.0055) | − (P = 0.013) | Treg | |||
| CD160 | − ( P = 0.024) * | Tgd, NKR | ||||
| CD208 (LAMP3) | + (P = 0.0025) | + (P = 0.017) | − (P = 0.036) | M1, DCA | ||
| CD244 (CD48L) | + (P = 0.041) | + (P = 0.0088) | − (P = 0.022) | Tgd, NKR, NKA, Treg | ||
| CD229 (LY9) | + (P = 0.0079) | + ( P = 5.0e‐5) * | + (P = 0.031) | − (P = 0.019) | T8, T4, T4R, Tgd | |
| CD258 (TNFSF14) | + (P = 0.0037) | + (P = 0.0017) | + (P = 0.0431) | − (P = 0.025) | NKA, M0, apoptosis related | |
| CD274 (PDL1) | + (P = 0.0029) | + (P = 0.016) | Th1, NK, T8, MØ | |||
| CD279 (PDCD1) | + (P = 0.023) | Tfh | ||||
| CD358 (TNFRSF21) | + (P = 0.045) | + (P = 0.031) | + (P = 0.00044) | − (P = 0.0044) | Apoptosis related (DR6) | |
| Other proteins | ||||||
| IL‐6 | + (P = 6.4e‐4) | + ( P = 1.9e‐4) * | − ( P = 2.0e‐4) * | In model. Inflammatory cytokine | ||
| IL‐18 | + (P = 0.024) | − (P = 0.017) | Inflammatory cytokine | |||
| GZMA | + (P = 0.047) | + ( P = 7.3e‐5) * | − (P = 0.0021) | Cluster. T8, T4R, Tgd, NKR, NKA | ||
| GZMB | + (P = 0.018) | + (P = 0.041) | + ( P = 1.4e‐5) * | − ( P = 1.7e‐4) * | Cluster. T8, T4A, Tgd, NKR, NKA | |
| GZMH | + (P = 0.0059) | + ( P = 3.4e‐5) * | − (P = 0.003) | Cluster. T8, Tgd, NKR, NKA | ||
| CA9 | + (P = 0.0061) | + (P = 0.0021) | − (P = 0.0016) | Hypoxia related | ||
| FASL | + (P = 0.0011) | − (P = 0.013) | Apoptosis related, NK | |||
| MMP12 | + (P = 0.0051) | + (P = 0.0089) | − (P = 0.012) | Cluster. DCR, DCA, M2 | ||
| VEGFA | + ( P = 0.036) * | + (P = 0.035) | + (P = 0.0061) | Angiogenesis related, Treg | ||
| ANG2 (ANGPT2) | + (P = 0.021) | + (P = 0.042) | + (P = 0.009) | − (P = 0.049) | Angiogenesis related, M1, M2 | |
| ESM1 | + (P = 0.0046) | + (P = 0.045) | + (P = 0.0015) | − (P = 0.026) | Angiogenesis related | |
| PDGFB | + (P = 0.0066) | + (P = 0.040) | Platelets, Angiogenesis related | |||
| LYN | + (P = 0.028) | + ( P = 3.8e‐4) * | − ( P = 2.3e‐4) * | Proto‐oncogene, B | ||
| TCL1A | + (P = 0.025) | + (P = 0.024) | B, T8, NK (proteomicsdb.org) | |||
| GAL9 (LGALS9) | + (P = 0.038) | + (P = 0.004) | − (P = 0.015) | B, T4, NK (proteomicsdb.org) | ||
a ‘Cluster’ (see Fig. 1B) or ‘Model’ (see Fig. 2A–C) refers to the analysis where the given protein was found to be altered. In addition, the following reports describe in which subset of leukocytes the respective proteins are expressed at elevated levels: Newman et al. (2015), Lyons et al. (2017), Strazza and Mor (2017), and Prat et al. (2017) and www.proteomicsdb.org. b‘12‐chemokine gene signature’ includes CCL2, CCL3, CCL4, CCL5, CCL8, CCL18, CCL19, CCL21, CXCL9, CXCL10, CXCL11, and CXCL13 (Prabhakaran et al., 2017). cAttract myeloid cells; see Turley et al. (2015). *P‐value in bold text: value after Bonferroni correction. † P‐value from the analysis of ER‐neg vs LumA samples (Table S5).